Explore the Potential with AI-Driven Innovation
This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.
Key features that set our library apart include:
partner
Reaxense
upacc
P52758
UPID:
RIDA_HUMAN
Alternative names:
14.5 kDa translational inhibitor protein; Heat-responsive protein 12; Reactive intermediate imine deaminase A homolog; Translation inhibitor L-PSP ribonuclease; UK114 antigen homolog
Alternative UPACC:
P52758; Q6FHU9; Q6IBG0
Background:
2-iminobutanoate/2-iminopropanoate deaminase, known by alternative names such as 14.5 kDa translational inhibitor protein and Heat-responsive protein 12, plays a crucial role in metabolism. It catalyzes the hydrolytic deamination of enamine/imine intermediates, potentially reducing the impact of toxic metabolites by facilitating ammonia release. Additionally, it promotes endoribonucleolytic cleavage of certain transcripts, enhancing the recruitment of the ribonuclease P/MRP complex.
Therapeutic significance:
Understanding the role of 2-iminobutanoate/2-iminopropanoate deaminase could open doors to potential therapeutic strategies.